European Investor
22 Oct 2025, 16:00
Thermo Fisher Scientific Inc. (NYSE: TMO) reported third-quarter 2025 revenue of $11.12 billion, a 5% increase year-on-year, with organic growth of 3%. GAAP diluted EPS was $4.27, roughly flat from a year earlier, while adjusted EPS rose 10% to $5.79.
GAAP operating income grew to $1.94 billion (up from $1.84 billion), and adjusted operating income reached $2.59 billion, yielding an adjusted operating margin of 23.3%, up 100 basis points year-over-year.
The company highlighted strong execution under its PPI Business System, continued innovation with new product launches such as the Oncomine Dx Express Test (FDA-approved for use with Dizal’s ZEGFROVY® in non-small cell lung cancer), and expanded research tools including the Olink Target 48 Neurodegeneration panel and the Talos 12 electron microscope.
Thermo Fisher also deepened its collaboration with OpenAI to accelerate the integration of artificial intelligence across operations and product development. Capital deployment included the acquisition of Solventum’s Filtration and Separation business and Sanofi’s Ridgefield, NJ sterile fill-finish site, along with $1.0 billion in share repurchases.
CEO Marc N. Casper said the results reflect “excellent operational performance” and reaffirmed confidence in achieving 2025 objectives while continuing to drive long-term value creation.
GAAP operating income grew to $1.94 billion (up from $1.84 billion), and adjusted operating income reached $2.59 billion, yielding an adjusted operating margin of 23.3%, up 100 basis points year-over-year.
The company highlighted strong execution under its PPI Business System, continued innovation with new product launches such as the Oncomine Dx Express Test (FDA-approved for use with Dizal’s ZEGFROVY® in non-small cell lung cancer), and expanded research tools including the Olink Target 48 Neurodegeneration panel and the Talos 12 electron microscope.
Thermo Fisher also deepened its collaboration with OpenAI to accelerate the integration of artificial intelligence across operations and product development. Capital deployment included the acquisition of Solventum’s Filtration and Separation business and Sanofi’s Ridgefield, NJ sterile fill-finish site, along with $1.0 billion in share repurchases.
CEO Marc N. Casper said the results reflect “excellent operational performance” and reaffirmed confidence in achieving 2025 objectives while continuing to drive long-term value creation.
